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Abstract
Lack of efficient culture systems for hepatitis C virus (HCV) has been a major obstacle in HCV research. Human liver cells grown in
a three-dimensional radial-flow bioreactor were successfully infected following inoculation with plasma from an HCV carrier. Subsequent
detection of increased HCV RNA suggested viral replication. Furthermore, transfection of HCV RNA transcribed from full-length cDNA
also resulted in the production and release of HCV virions into supernatant. Infectivity was shown by successful secondary passage to a new
culture. Introduction of mutations in RNA helicase and polymerase regions of HCV cDNA abolished virus replication, indicating that
reverse genetics of this system is possible. The ability to replicate and detect the extracellular release of HCV might provide clues with
regard to the persistent nature of HCV infection. It will also accelerate research into the pathogenicity of HCV, as well as the development
of prophylactic agents and new therapy.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
More than 100 million people are infected with hepatitis
C virus (HCV) worldwide, and many are prone to develop-
ing chronic hepatitis with subsequent cirrhosis and hepato-
cellular carcinoma (HCC) (Choo et al., 1989; Kuo et al.,
1989; Saito et al., 1990). Measures to eliminate HCV from
carriers before progressive and degenerative liver diseases
develop are needed. However, studies aimed at elucidating
the mechanism behind persistent HCV infection have been
hampered by lack of an efficient in vitro culture system
capable of supporting viral replication.
Many attempts have been made to culture HCV in vitro.
However, to date, only limited HCV replication was sug-
gested by reverse transcription-polymerase chain reaction
(RT-PCR) techniques, and HCV-specific proteins were not
generally detected (Ito et al., 2001; Kato and Shimotohno,
1999; Thomson and Liang, 2000). Infectious cDNA clones
have been successfully developed for positive-sense RNA
viruses (Boyer and Haenni, 1994). Full-length HCV cDNA
clones have also been successfully used to infect chimpan-
zees in in vivo transfection experiments (Kolykhalov et al.,
1997, 2000; Yanagi et al., 1997). Furthermore, replication
of genome-length dicistronic HCV RNA was shown in a
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human liver cell line when HCV RNA was dicistronically
transfected together with selective markers (Ikeda et al.,
2002; Pietschmann et al., 2002). Although replication of the
entire HCV genome was also observed, any infectious HCV
virions could not be detected (Pietschmann et al., 2002).
Thus, viral RNA replication and synthesis of fully processed
viral proteins may not be sufficient to produce infectious
virus. One or more host factor(s) provided only by permis-
sive cells may be required for the assembly of infectious
virions. Alternatively, monolayer cultures of mammalian
cells, typically human liver-derived cell lines, may not per-
mit the assembly and release of HCV from cells.
Nagamori et al. established a three-dimensional (3D)
radial-flow bioreactor (RFB) system, in which human liver
cells retained their differentiated hepatocyte functions and
morphological appearance for an extended period of time
(Kawada et al., 1998). This system was originally designed
to develop artificial liver tissue (Kawada et al., 1998; Mat-
suura et al., 1998). However, in this study, we utilized the
system to examine cells transfected with full-length HCV
RNA or inoculated with infectious serum. Although the titer
was not particularly high, propagation of HCV in vitro was
clearly shown. Furthermore, infectious virus was released
into the supernatant in the absence of obvious cell lysis.
Results
FLC4 cell culture in RFB system
We found that cells from a human hepatocellular carci-
noma-derived cell line, FLC4 (Functional Liver Cell 4)
(Aoki et al., 1998), produced albumin at a rate of 18 g/105
cells/day, when cultured in the RFB system. In conventional
monolayer cultures, FLC4 cells produced albumin at a rate
of 2.5 g/105 cells/day.
-Fetoprotein production by FLC4 cells also differed
among the two culture systems (7 g/105 cells/day were
produced by cells in the RFB system versus an undetectable
amount by cells in the monolayer culture). Production of
albumin and -fetoprotein by FLC4 cells in the RFB culture
continued for more than 100 days without cell passage,
during which time the temperature was reduced from 37 to
32°C, causing a gradual increase in oxygen consumption.
Transmission electron microscopy (TEM) has shown
maintenance of tight junctions among RFB-cultured FLC4
cells and normal intercellular spaces (Fig.1A). Scanning
electron microscopy (SEM) has shown that, unlike FLC4
cells in monolayer cultures, FLC4 cells cultured in the RFB
system retain structurally intact microvilli on their surface
(Fig. 1B). RFB culture is therefore thought to provide an
environment in which the natural architecture and function
of cells are maintained. We tested the replication of HCV
under these conditions as a model of HCV replication in
vivo.
Infection experiments
First, we inoculated FLC4 cells with infectious human
plasma in RFB culture. The infectious plasma (no. 6) was
derived from a healthy HCV carrier and its infectivity was
eventually proven after posttransfusion hepatitis C was ob-
served in a patient that had received the carrier’s blood
(Takeuchi et al., 1990; Aizaki et al., 1998). Afterward, the
infectivity of the carrier’s plasma was tested by inoculation
of chimpanzees, and its titer was determined to be 105.5
chimpanzee infectious doses per milliliter (Sugitani and
Shikata, 1998).
Fig. 1. FLC4 cells in the RFB. (A) Transmission electron micrograph image of FLC4 cells cultured in the RFB. Scale bar shows 10 m. (B) Scanning electron
micrographs showing FLC4 cells attached with the RFB matrix. Scale bar shows (B).
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After cells (1  109) were inoculated with 1 ml of the
plasma in RFB culture by infusion, HCV RNA was detected
by PCR in the culture fluid for 2 days. This was thought to
be due to residual virus following the infusion. RNA was
not detected in the culture fluid for the next 2 weeks (less
than 50 copies/ml). HCV RNA was then detected on day 16
postinfection (p.i.) and reached 104 – 105 copies/ml by days
19 and 23 p.i. (Table 1). After this, HCV RNA was detected
in the culture fluid for more than 80 days by the qualitative
assay (data not shown). Subsequent experimentation using
the same cells and inoculum reproduced this profile of HCV
RNA detection in the culture fluid (data not shown). In this
experiment, the cells were harvested on day 14, and further
culture was discontinued. Intracellular HCV core protein
levels were as high as 75 pg/mg of total cellular protein in
the cells. Although the precise number of cells supporting
virus replication could not be determined, this level of core
protein expression is almost equivalent to that observed in
the liver tissue of chronic hepatitis C patients (Koike et al.,
2002).
The hypervariable regions (HVR) of HCV RNA detected
on day 23 p.i. were compared to those of plasma no. 6
(Table 2). Plasma no. 6 (donor plasma) was found to contain
a mixture of clones with different HVR sequences, but more
than half of these contained A1 sequences (Sugitani and
Shikata, 1998). After transmission, these mixed clones con-
verged until one clone was primarily detected (clone A1) in
infected chimpanzees (Chimp.) (Sugitani and Shikata,
1998), and in the human hepatitis patient, who received no.
6 plasma for transfusion (Recip.) (Aizaki et al., 1998).
Interestingly, of the 20 clones tested in this RFB culture
study, 19 had A1 clone sequences. These data suggest that
the HCV RNA detected was not that of the infused virus
but, rather, it appears that the RFB culture selectively sup-
ported the replication of certain clones. Clones having A1
sequences may have a replication advantage in RFB culture.
Table 1
HCV infection of FLC4 cells cultured in the RFB following inoculation
with the plasma
Days HCV RNAa
(log10 copies/ml)
ALT (IU/l)
2  7
0b 5 2
1  NTc
2  NT
3  2
4  NT
5  2
7  NT
9  2
11  NT
12  2
14  NT
16  2
19 4–5 2
23 4 2
26  2
a HCV RNA in the culture fluids was determined by qualitative and
quantitative RT-PCR. Log of copy numbers identified by the quantitative
assay are shown. , positive by the qualitative assay but below the
detection limit (103 copies/ml) by the quantitative one., negative by both
of assays.
b On the day 0, plasma no. 6 was inoculated.
c NT, not tested.
Table 2
Comparison of amino acid sequences of HVR among HCV clones derived from plasma no. 6
Species Sequence of HVRa Number of clones
Donorb Chimp. Recip. RFB
384 410
A1 H Y R V T R G V Q G H V T S T L T S L F R P G A S Q K 11 20 2 19
A2 S - - - - - - - - - - - - - - - - - - - - - - - - - -c 1 0 0 0c
A3 - - - - - - - - - - - - - - - - - - - - - - - L - - - 1 0 0 0
A4 - - - - - - - - - - - - - - - - - - - - - - - - F - - 0 0 0 1
B1 N - H - - - - - - - - - - - - - - - - - - - - - - - - 1 0 0 0
B2 N - H - - - A - - - - G A F G - - - - - Q - - - - - - 3 0 0 0
B3 N - H - - - A - - - - G A F - - - - - - T S - - - - - 0 0 1 0
B4 D - H - - - A - - - - G A F - - - - - - T S - - - - - 3 0 0 0
B5 D - H - - - A - - - - G A F Q - - - - - T S - - - - - 0 0 1 0
B6 D - H - - - A - - - - G A F Q - - - - - T S - - - - R 0 0 1 0
B7 D - H - - - A - - - - G A F H - - - - - T S - - - - - 0 0 2 0
B8 D - H - - - A - - C - G A F H - - - - - T S - - - - - 0 0 1 0
C1 N - H - - - - - - - R - A - K - - - F - T - - P - - - 0 0 1 0
D1 - - H - - - - - - - - - - - - - - - F K - S - - - - - 0 0 1 0
20 20 10 20
a Sequences of HVR in HCV clones recovered from the culture fluid of the RFB (RFB), the plasmas of a donor (Donor), a chimpanzee (Chimp.), and a
recipient (Recip.) are shown.
b The sequences and diversity in Donor, Chimp., and Recip. are from Sugitani and Shikata (1998), and Aizaki et al. (1998).
c Dashes represent amino acid residues identical to the clone A-1.
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Transfection experiments
The above results suggest that RFB culture supports the
replication and release of HCV in culture fluid. To confirm
this, we transfected cells in RFB culture with HCV RNA.
RNA derived from an infectious full-length HCV cDNA
clone (H77c) (Yanagi et al., 1997) was used. This clone was
derived from HCV genotype 1a and was proven infectious
by direct inoculation into chimpanzee livers.
Cells were transfected with HCV RNA and cultured
using the RFB system. HCV RNA was assayed by RT-PCR
using samples of culture fluid. As in the infection experi-
ments described above, the amount of viral RNA in the
culture fluid declined immediately after transfection. At
days 44, 47, 51, and 54 posttransfection (p.t.), HCV RNA
was positive by the qualitative assay but below the detection
limit (103 copies/day) by the quantitative one (Aizaki et al.,
1998). However, the sample collected on day 57 p.t. indi-
cated HCV RNA levels as 105 – 106 copies/day. This level
remained here for 100 days of culture (Fig. 2A, open circles
and solid line). In addition, HCV core protein gradually
increased in the culture fluid until a maximum level of
approximately 13.2 pg/day was reached on day 106 p.t.
(Fig. 2B, filled squares and dotted line). The relative
amounts of HCV core protein (13.2 pg/day) and HCV RNA
(105 – 106 copies/day) detected on day 106 p.t. are consis-
tent with previously reported data on native HCV virions
(Kashiwakuma et al., 1996). Since ALT levels did not
increase within the culture fluid (Fig. 2B, open squares and
solid line), direct hepatocyte injury did not appear to result
from HCV replication.
To determine whether the HCV RNA detected was pack-
aged within virions, the culture fluid collected on days 57
and 96 p.t. was treated with RNase and examined by quan-
titative RT-PCR. As shown in Fig. 2C, the HCV nucleic
acid was first confirmed to be RNA. However, the RNA was
RNase resistant, suggesting that it is contained within viri-
ons. The RNase resistance might also indicate HCV RNA of
Fig. 2. HCV propagation in FLC4 cells in RFB culture following transfection with the RNA derived from the infectious cDNA clone. (A) HCV RNA titers
in the culture fluid after transfection of the infectious HCV RNA H77c (E), helicase inactive mutant RNA H77cHel- (‚), and RdRp inactive mutant RNA
H77cRdRp- (F). On the day 0, the full-length HCV RNA H77c was transfected. HCV RNAs at days 44, 47, 51, and 54 were positive, but their RNA titers
were 103 copies/ml. (B) ALT levels () and the amount of HCV core protein () in the culture fluid after transfection of H77c, respectively. (C) Culture
fluids of the H77c transfectant were treated with () or without () RNase A. Samples were then amplified by RT-PCR with () or without () enzyme
in the RT step. The culture fluids collected on day1, 57, and 96 after inoculation, patient plasma, and the cell-culture medium added with 6 104 molecules
of HCV RNA transcript were analyzed. (D) Negative-strand-specific RT-PCR, Lane 1, cellular RNA without added synthetic RNA. Lanes 2 and 3, with added
synthetic negative () and positive ()-strand RNA, respectively. Lane 4, cellular RNA from the cells harvested on the day 110 p.t. (E) HCV clones
recovered from the culture fluids of the RFB. (Top) Schematic presentation of the complete HCV genome. The ORF with the structural proteins (shaded box)
located in the amino-terminal portion of polyprotein, and the remainder encodes the nonstructural protein (NS2 to NS5B). (Middle) The positions and
frequencies. Overlapping RT-PCR products were sequenced and the mutations observed in nonstructural protein regions are illustrated, along with the
frequency with each arose. The amino acid number is indicated above the H77c sequence.
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the double-stranded replicative form. Nevertheless, such
RNA, if any, trapped in membranous structures of the cells
may not be conferred resistance to nucleases. In the RFB
system, RNase-resistant HCV RNA was not detected after
transfection of mutant clones (described later). Furthermore,
in cells harvested on day 110 p.t., negative-strand HCV
RNA was detected by tagged RT-PCR (Fig. 2D).
To verify that this system supports the replication of
transfected HCV RNA, we constructed two mutated full-
length HCV RNAs, termed H77cHel and H77cRdRp,
containing lethal mutations of helicase and polymerase,
respectively. After transfection, the residual RNA of these
mutant clones gradually declined in the culture fluid, and no
RNA was detected by RT-PCR after day 38 and 40 p.t., for
H77cHel and H77cRdRp, respectively (Fig. 2A,
H77cHel: open triangles; H77cRdRp: filled circles).
Thus the detection of HCV RNA 44 days after transfection
of wild-type HCV RNA must have been due to actual viral
replication.
To confirm HCV replication and to determine whether
mutations arose during the course of the study, we deter-
mined the nucleotide sequences of entire nonstructural re-
gions of the clone detected on day 110 p.t. and compared
them with the original clone (Fig. 2E). We observed 43
substitution mutations, all of which resulted in amino acid
changes. This is not derived from RT errors during RT-PCR
amplification because similar sequence changes were seen
in the independent RT-PCR reaction. In particular, muta-
tions of V1700S in the NS4A, E1937G in the NS4B, and
K1298N in the NS3 regions were frequently observed (in
60% or more of the sequenced clones), which suggests that
these mutations might enhance RNA replication within the
FLC4-RFB system. We are now analyzing whether or not
transcripts with these mutations enhance infectivity or have
a replication advantage in RFB culture.
Late-stage culture fluid (80 to 110 days posttransfection)
was collected, concentrated, and examined by TEM. A
number of spherical particles, between 30 and 80 nm in
diameter, were observed, and probably represent two enti-
ties of approximately 30 and 60 nm in size (Fig. 3A). The
suspension was then fractionated by spinning within a con-
tinuous 10–60% (w/w) sucrose gradient. The fractions were
then treated with Triton X-100/NaOH/polyethylene glycol
and assayed for HCV core protein. The core protein was
detected in both 1.07 and 1.20 g/ml fractions, while HCV
RNA was predominantly detected in fractions of 1.03–1.09
g/ml (Fig. 3B). Although quantitative assays to detect HCV
envelope proteins have not been developed, the lower den-
sity fraction observed in this study (1.03–1.09 g/ml) might
reflect the presence of HCV particles (1.03–1.12 g/ml), as
previously observed in the serum of hepatitis C patients
(Kanto et al., 1994; Kaito et al., 1994). The higher density
fraction, in contrast, may represent empty particles without
RNA. To distinguish between the particles observed in these
fractions, an indirect immunogold electron microscopic
study was carried out (Figs. 3C and D). Spherical virus-like
particles, 55 to 60 nm in diameter, in the 1.07 g/ml fraction
reacted with monoclonal antibody to HCV E1 protein. We
did not observe any specific reactions of concentrated su-
pernatant from transfected cells with anti-Histidine antibody
(Fig. 3E).
The secondary passage
The virus particle-containing supernatant collected at
days 93, 94, and 95 p.t. was pooled and transferred to a fresh
RFB culture of FLC4 cells. No HCV RNA was detected in
supernatant collected at days 1–16 p.i. However, HCV RNA
was detected on day 18, 24, and 28 p.i. The HVR sequences
of this HCV RNA were mostly (90%) A1 clone sequences.
New clones with a single base change were detected after
another 14 days. In addition, HCV core protein was detected
in the culture fluid on day 24 and 28 p.i. (Table 3). These
results further suggest that HCV is produced in RFB culture
and that released HCV is infectious.
Discussion
Despite numerous efforts to grow HCV, full replication
of HCV has not been achieved in conventional monolayer
cultures using any type of cell (Kato and Shimotohno, 1999;
Thomson and Liang, 2000). Even when HCV RNA is de-
tected by PCR in monolayer cultures, synthesis of newly
synthesized HCV-specific proteins is not observed (Barten-
schlager and Lohmann, 2001). A robust and reliable cell-
culture system by which to grow HCV is urgently needed
(Randall and Rice, 2001).
Recent reports have demonstrated HCV replication in
human hepatocytes following transplantation into mice (Ilan
et al., 2002; Mercer et al., 2001). This model provided a
useful system to evaluate anti-HCV agents. However, re-
searchers have yet to isolate infectious HCV virions.
In this connotation, the establishment of a HCV replica-
tion system (engineered HCV minigenomes) has been a real
breakthrough in recent HCV research (Lohmann et al.,
1999; Blight et al., 2000). This has also made reverse
genetic HCV research possible. Furthermore, the ability to
passage these cells has revealed that clones with “adaptive”
mutations eventually become dominant (Blight et al., 2000;
Lohmann et al., 2001; Krieger et al., 2001). However, the
consensus sequences responsible for enhancement of HCV
RNA replication have not been identified, even after exam-
inations of the same clone (type 1b) and hepatocyte cell line
(Huh-7 cells). This system was first developed to replicate
only the nonstructural region of HCV genome, but further
developed to enable replication of the full-length HCV
genome. Although HCV RNA was synthesized, along with
all properly processed HCV proteins, infectious virions
were not produced (Ikeda et al., 2002; Pietschmann et al.,
2002). Host cell factor(s) essential for virus assembly and
release might not be provided, even by Huh-7 cells, which
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Fig. 3. Analysis of HCV-like particles in culture medium. (A) Culture fluid of the H77c transfectant was concentrated, stained with uranyl acetate, and
examined by TEM. (B) HCV core protein in fractions from sucrose density gradient centrifugation. Amounts of HCV core protein (E) and buoyant densities
(F) are shown. (C, D, E) Immunoelectron microscopy of the particles purified by sucrose gradient centrifugation. (C, D) Virus-like particles reacted with
mouse monoclonal antibody against HCV E1 protein at a dilution of 1:10, and their antibody haloes were identified by binding to goat anti-mouse
IgG-conjugated colloidal gold particles (6 nm) at a dilution of 1:20. (E) Control reaction using mouse monoclonal antibody against histidine residues antigen.
The scale bars represent 50 nm.
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are capable of hosting viral RNA replication and HCV
protein synthesis.
The results presented in this article clearly indicate that
HCV replicates in FLC4 cells in the RFB system. In this
study, we repeated the infection, transfection, and second-
ary passage experiments three times and obtained reproduc-
ible results. We also performed a mock-infected RFB cul-
ture for 4 months, during which time culture supernatant
was harvested every week and examined for HCV RNA and
HCV core protein. Negative results were obtained for both
(data not shown).
In the culture medium of FLC4 cells in RFB culture, 106
– 107 copies/day of HCV were detected 2–3 weeks after
infection, and 105 – 106 copies/day were detected 2–4 months
after transfection. Although the viral growth of HCV in culture
remains inefficient compared to that of other known viruses,
this is the first report to unequivocally demonstrate HCV rep-
lication in tissue culture, as well as the production of infectious
HCV derived from full-length HCV RNA.
The reason for different profiles of detection of HCV
RNA and core protein is unclear (Fig. 2B). It is possible that
the two assays have different sensitivities. Differences in the
half-lives of viral RNA and HCV core protein may be also
explain the difference. Nonetheless, the slow but gradual
increase in HCV RNA and core protein observed in this
study excludes the possibility that the results are due to
HCV contamination or detection of the originally infused
HCV RNA. These results also suggest that selection of
clones capable of viral replication occurs during FLC4/RFB
culture. Furthermore, it was shown that the viral quasispe-
cies have changed before and after passages. Efforts to
select clones with adaptive mutations enhancing both RNA
replication and the production of infectious progeny are
ongoing.
The key point of this work is the RFB culture, which
allows liver cells to maintain their physiological function
for a long time in culture. The RFB is a vertically extended
cylindrical matrix with porous bead microcarriers having a
honeycomb-like structure. This structure enables contact
between cells and circulating components, including oxy-
gen and nutrients, without excessive shear stress. The RFB
has an effective air space ratio of 50%; thus, the microcar-
riers have much of their surface area exposed, which sup-
ports the long-term viability of the cells in culture. Cells
cultured in the RFB system maintain their polarity within a
well-defined 3D structure, having tight intercellular junc-
tions and close connectivity with other epithelial cell mem-
branes. These characteristics are important for the sustained
function of liver cells in culture, including secretory and
endocytic/transcytotic hepatocyte pathways.
A number of enveloped viruses have been reported to
mature at distinct membrane domains within monolayers of
polarized epithelial cells. For example, paramyxoviruses
and orthomyxoviruses bud from the apical surface, while
rhabdoviruses, retroviruses, and baculoviruses bud from a
basolateral domain (Boulan and Sabatini, 1978). Similarly,
FLC4 cells in the RFB are thought to maintain their polarity
in a well-defined 3D structure, which is necessary for the
replication and secretion of HCV.
The use of FLC4 cells may contribute to the success of
this system. We have previously shown that this cell line
supports efficient HCV structural gene expression by a
recombinant adenovirus vector (Aoki et al., 1998). The
results of this report also suggest that some host factors
which increase the efficiency of translation of HCV mini-
gene RNA are present in FLC4, but not other cells, includ-
ing several commonly used human hepatoma cell lines.
Furthermore, using a cell fusion assay, we recently found
that FLC4 cells exhibit a high affinity for cell fusion with
CHO cells expressing HCV envelope proteins on their sur-
face (Takikawa et al., 2000). However, FLC4 cells in con-
ventional monolayer cultures were not observed to support
HCV replication following infection with no. 6 plasma.
Although a small amount of virus was detected by PCR on
day 19 p.i., less than 1 to 10–100th of the amount of virus
per cell obtained with RFB culture was observed (data not
shown). HCV RNA was not detected beyond day 19 p.i.
We are now attempting to simplify the method of RFB
culture, by culturing fewer cells to better monitor HCV
replication and intracellular events. In the immediate future,
we will attempt to confirm the infectivity of HCV isolated
from RFB culture by inoculation of chimpanzees. In addi-
tion, we would like to study the intracellular localization of
processed HCV proteins, as well as virus assembly and the
effects of specific antibodies and inhibitors. All of these
things need to be done. Nevertheless, the evidence of infec-
tivity of HCV RNA shown in the present work illustrates
the potential of reverse genetics to delineate the mechanism
Table 3
Secondary passage of HCV produced from the viral RNA transfection in
the RFB culture
Days HCV RNAa Coreb (pg/day)
2  0
0c  5.3
1  2.1
3  0
5  0
7  0
9  0
11  0
13  0
16  0
18  0
20  0
22  0
24  6.9
28  14.5
a HCV RNA was detected qualitatively by RT-PCR (positive, ; neg-
ative, ).
b Core antigen was measured by the EIA method.
c Supernatant fluid of the RFB culture transfected with HCV RNA was
transferred to new FLC4 cells in the RFB on day 0.
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of HCV replication at a molecular level. This system will no
doubt prove quite useful for studying the mechanism of
persistent HCV infection and to evaluate the efficacy of
vaccines, as well as various HCV specific inhibitors.
Materials and methods
Inoculum
We used plasma (no. 6) from a donor known to carry
infectious HCV. Competitive RT-PCR detected 105 ge-
nome/ml of HCV RNA in the plasma (Sugitani and Shikata,
1998). pCV-H77C, which contains a full-length cDNA
clone of strain H77 of HCV, was kindly provided by Dr. J.
Bukh, National Institutes of Health, USA (Yanagi et al.,
1997). We also constructed two full-length mutant clones
(H77cHel- and H77cRdRp-) of HCV, containing D1316A
(4286 to 4289), and G2737A (8551 to 8552), D2738A
(8554), and D2739G (8557 to 8559) substitutions, respec-
tively (Kolykhalov et al., 2000).
RFB culture of FLC4 cells
We developed a RFB culture system (Able, Japan)
(Kawada et al., 1998; Matsuura et al., 1998) of FLC4 cells,
produced from the cloning of JHH4 cells, in an attempt to
maintain hepatocyte function in culture for an extended
period of time. The RFB system, having an area of 2.7 m2,
was seeded with 1  109 FLC4 cells. Culture medium
containing 2% FCS was added at a flow rate of 50 ml/day.
To monitor the viability of cells, oxygen and glucose con-
sumption, as well as albumin secretion, were continuously
monitored throughout the duration of the study. The culture
temperature was reduced from 37 to 35°C immediately
following inoculation with plasma, and again to 32°C on
day 51 p.i. to maintain continual slow growth of cells. As a
consequence, oxygen consumption increased steadily,
reaching 250 mg/day by day 30 p.i. and 350 mg/day by day
70 p.i. Despite the effects of low temperature on the culture,
albumin secretion remained above 75 g/ml throughout the
culture period of 100 days.
Infection and transfection
In the infection experiments, FLC4 cells were seeded in
the RFB and cultured in ASF medium (Ajinomoto, Tokyo,
Japan), containing 2% fetal calf serum, at a flow rate of 100
ml/day. One milliliter of plasma no. 6 was added, after
which HCV RNA and ALT levels were measured in the
culture fluid. To maintain an oxygen concentration of less
than 1.0 ppm at the RFB outlet during culture, the culture
temperature was gradually reduced from 37 to 32°C.
In the transfection experiments, serum-free ASF medium
was added to FLC4 cells in RFB culture at a rate of 50
ml/day. pCV-H77C, pCV-H77cHel-, or pCV-H77cHel- was
linealized with XbaI, and 10 g of each RNA transcript was
mixed with lipofectin (Invitrogen, Carlsbad, CA) and di-
luted with 10 ml of Opti-MEM (Invitrogen). The mixture
was then used to inoculate cells in the RFB.
For secondary passage, supernatant was collected on
days 93, 94, and 95 p.t. (pooled to approximately 150 ml)
and frozen at 80°C, until which time it was thawed and
centrifuged at 8000 g for 15 min. After this, the supernatant,
containing approximately 1.5  106 copies of HCV, was
transferred to new FLC4 cells in RFB culture. Fifty milli-
liters of culture fluid was collected every day and replaced
with 50 ml of new, fresh medium.
Analysis and quantitation of HCV RNA
HCV RNA in the medium was qualitatively detected by
RT-PCR as described previously (Aizaki et al., 1998).
Quantitative determination of HCV RNA was performed
according to the competitive PCR method described by
Kaneko et al. (1992). The limit of detection for HCV RNA
by quantitative PCR was 103 copies/ml (Aizaki et al., 1998).
RT-PCR was performed independently in two different lab-
oratories (National Institute of Infectious Diseases and Mit-
subishi Kagaku Bio-clinical Laboratories, Japan), and the
same results were obtained. The nucleotide and amino acid
sequences of HVRs of HCV envelope glycoprotein E2 were
compared. Treatment with RNase was done as described
previously by Kolykhalov et al. (1997). Negative-stranded
HCV RNA was detected by strand-specific PCR as de-
scribed previously by Lanford et al. (1994). Synthetic pos-
itive-and negative-strand RNAs encompassing the 5 un-
translated region of HCV were prepared by in vitro
transcription using T7 RNA polymerase, followed by ex-
tensive purification with DNase to remove DNA. The pu-
rified RNAs were mixed with cellular RNA from FLC4 to
mimic the conditions of transfected cells and to check for
the generation of false positives by PCR. PCR products
from one round of amplification were analyzed by agarose
gel electrophoresis.
Enzyme immunoassay for HCV core antigen
The culture medium was centrifuged at 8000 g for 90
min, after which the supernatant was centrifuged at 100,000
g for 3 h. The precipitates were suspended in lysis buffer
(Promega, Madison, WI) and HCV core antigen was mea-
sured using the highly sensitive enzyme immunoassay
(EIA) method (Kashiwakuma et al., 1996).
Electron microscopy study
Cell samples for TEM and SEM were prepared as de-
scribed previously (Kawada et al., 1998). Briefly, FLC4
cells in RFB culture were fixed in 2.5% glutaraldehyde in
0.1 M phosphate buffer (pH 7.4). After treatment with 0.1%
osmium tetroxide in the same buffer, specimens were de-
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hydrated in ethanol, after which they were embedded in a
mixture of propyloxide and EPOK812 epoxy resin. Thin
sections were examined with a transmission electron micro-
scope (JEOL DEM1200-EX, Nihon Denshi Co., Japan).
FLC4 cells attached to microcarriers were fixed to the ob-
servation table and dehydrated, after which they were sub-
merged in 100% isoamine acetate. Samples coated with
carbon and gold were observed with a scanning electron
microscope (JEOL-35CF, Nihon Denshi Co.).
To analyze the virus-like particles, culture fluid of cells
transfected with HCV RNA was collected and concentrated
by ultracentrifugation. The pellet obtained by centrifugation
was suspended in 1.5 ml of ASF medium and one-third of
the suspension was reconcentrated. After this, the resultant
pellet was suspended in 3 l of ASF medium and applied to
a formvar-carbon grid for negative staining. For IEM study,
mouse monoclonal antibody against HCV E1 protein (1:10
dilution) and goat anti-mouse IgG-conjugated colloidal gold
particles (6 nm; 1:20 dilution) were used as first and second
antibodies, respectively.
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